10/12/2020 1 Diabetes Update 2020 Case Studies in Diabetes Anupam Kotwal, MBBS Assistant Professor Cyrus Desouza, MBBS Professor and Chief Division of Diabetes, Endocrinology and Metabolism University of Nebraska Medical Center Learning objectives 1.Modify diabetes therapies based on diabetes complications and comorbidities 2.Adjust insulin regimen based on glycemic control
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
10/12/2020
1
Diabetes Update 2020Case Studies in Diabetes
Anupam Kotwal, MBBSAssistant Professor
Cyrus Desouza, MBBSProfessor and Chief
Division of Diabetes, Endocrinology and MetabolismUniversity of Nebraska Medical Center
Learning objectives1.Modify diabetes therapies based on
diabetes complications and comorbidities
2.Adjust insulin regimen based on glycemic control
10/12/2020
2
DisclosuresAnupam Kotwal: Nothing to disclose
Cyrus Desouza:• Novo Nordisk• AstraZeneca• Bayer
Case 1A 57-year-old man with type 2 diabetes for 12 years, hypertension, dyslipidemia, CAD and MI status post stent placement 9 months ago. He takes metformin, statin, aspirin, lisinopril. His BMI is 38 kg/m2 and HbA1c is 8.4%. What is the next best step in diabetes management?
Case 1A 57-year-old man with type 2 diabetes for 12 years, hypertension, dyslipidemia, CAD and MI status post stent placement 9 months ago. He takes metformin, statin, aspirin, lisinopril. His BMI is 38 kg/m2 and HbA1c is 8.4%. What is the next best step in diabetes management?
Pharmacologic Approaches to Glycemic Management: Standards of Medical Care in Diabetes - 2020. Diabetes Care 2020;43(Suppl. 1):S98-S110
10/12/2020
4
LEADER (Liraglutide)
Marso, S. P., et al. (2016). "Liraglutideand Cardiovascular Outcomes in Type 2 Diabetes." New England Journal of Medicine 375(4): 311-322.
Primary outcome: First occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke
SUSTAIN-6 (Semaglutide)Marso, S. P., et al. (2016). "Semaglutideand Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine 375(19): 1834-1844.
Primary outcome: First occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke
Gerstein, H. C., et al. (2019). "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial." The Lancet 394(10193): 121-130.
OR (2nd line)SGLT-2 inhibitor with proven CVD benefit• Empagliflozin > Canagliflozin
Case 2A 60-year-old man with type 2 diabetes for 8 years, hypertension, dyslipidemia, coronary artery disease, systolic heart failure (LVEF 35%), recently admitted with heart failure exacerbation. He takes metformin for diabetes. His BMI is 40 kg/m2 and HbA1c is 8.5%. What is the next best step in diabetes management?
Case 2A 60-year-old man with type 2 diabetes for 8 years, hypertension, dyslipidemia, coronary artery disease, systolic heart failure (LVEF 35%), recently admitted with heart failure exacerbation. He takes metformin for diabetes. His BMI is 40 kg/m2 and HbA1c is 8.5%. What is the next best step in diabetes management?
Pharmacologic Approaches to Glycemic Management: Standards of Medical Care in Diabetes - 2020. Diabetes Care 2020;43(Suppl. 1):S98-S110
10/12/2020
7
DAPA-HF (Dapagliflozin)
McMurray, J. J. V., et al. (2019). "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction." New England Journal of Medicine 381(21): 1995-2008.
58% did NOT have DMPrimary outcome: Worsening HF (hospitalization or an urgent visit resulting in intravenous therapy for HF) or cardiovascular death
EMPA-REG (Empagliflozin)
Zinman, B., et al. (2015). "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes." New England Journal of Medicine 373(22): 2117-2128.
Primary outcome: First occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke
10/12/2020
8
EMPEROR-Reduced(Empagliflozin)
Packer, M., et al. (2020). "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure." New England Journal of Medicine.
Primary outcome: First occurrence of cardiovascular death or hospitalization for HF
Hospitalization for heart failure reduction• Dapagliflozin > Empagliflozin >
Canagliflozin• Dapagliflozin and Empagliflozin
improve worsening HF and CV death in patients without diabetes as well
10/12/2020
9
Case 3A 62 year-old woman with type 2 diabetes for 7 years, hypertension, diabetic nephropathy, CKD. She takes metformin 1000 mg daily. Her BMI is 34 kg/m2, HbA1c is 8.2%, eGFR is 42 ml/min/1.73m2, urine albumin/creatinine is 320 mg/g. What is the next best step in diabetes management?
Case 3A 62 year-old woman with type 2 diabetes for 7 years, hypertension, diabetic nephropathy, CKD. She takes metformin 1000 mg daily. Her BMI is 34 kg/m2, HbA1c is 8.2%, eGFR is 42 ml/min/1.73m2, urine albumin/creatinine is 320 mg/g. What is the next best step in diabetes management?
Pharmacologic Approaches to Glycemic Management: Standards of Medical Care in Diabetes - 2020. Diabetes Care 2020;43(Suppl. 1):S98-S110
CREDENCE (Canagliflozin)
Perkovic, V., et al. (2019). "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy." New England Journal of Medicine 380(24): 2295-2306.
Primary outcome: ESKD (dialysis, transplantation, or sustained eGFR of <15 ml/min/1.73 m2), doubling of the serum Cr, or death from renal or cardiovascular causes
10/12/2020
11
DAPA-CKD (Dapagliflozin)
• Participants with eGFR 25-75 ml/min/1.73m2 and UACR 200-5000 mg/g (n=4304)
• Primary endpoint (eGFR decline >50%, ESKD, kidney or CVD death) significantly reduced by 39%
• HR 0.61 (95% CI 0.51–0.72; p=0.000000028)• All secondary endpoints met, including all-cause
mortality significantly reduced by 31%• Benefit was consistent in patients with and without
type 2 diabetes
“A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD).” ClinicalTrials.gov
LEADER (Liraglutide)
Time to first renal event (secondary outcome):Macroalbuminuria, doubling of serum Cr, ESRD, renal death
Marso, S. P., et al. (2016). "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes." New England Journal of Medicine 375(4): 311-322.
10/12/2020
12
For patients with type 2 diabetes and CKD, with or without cardiovascular disease• Consider the use of an SGLT2 inhibitor shown
to reduce CKD progression (Canagliflozin is the only one with FDA indication) or, if contraindicated or not preferred, a GLP-1 receptor agonist shown to reduce CKD progression
Case 4A 75 year-old woman with type 2 diabetes for 20 years, hypertension, CKD (eGFR 50 ml/min/1.73m2), osteoporosis, dependent pedal edema. She has history of several UTI, and has poor appetite. She takes metformin. Her BMI is 24 kg/m2 and HbA1c is 8.1%. She refuses insulin. What is the next best step in diabetes management?
Case 4A 75 year-old woman with type 2 diabetes for 20 years, hypertension, CKD (eGFR 50 ml/min/1.73m2), osteoporosis, dependent pedal edema. She has history of several UTI, and has poor appetite. She takes metformin. Her BMI is 24 kg/m2 and HbA1c is 8.1%. She refuses insulin. What is the next best step in diabetes management?
Pharmacologic Approaches to Glycemic Management: Standards of Medical Care in Diabetes - 2020. Diabetes Care 2020;43(Suppl. 1):S98-S110
10/12/2020
14
If eGFR <45 ml/min/1.73m2
• Linagliptin• Dose-reduced Sitagliptin
Case 5A 55-year-old man with uncontrolled type 2 diabetes despite metformin and glargine once daily titrated to 40 units. HbA1c is 8.5%, AM fasting blood glucose range 120-140 mg/dL, prandial blood glucose range 180-200 mg/dL. His BMI is 36.8 kg/m2. What is the next best step in diabetes management?
Case 5A 55-year-old man with uncontrolled type 2 diabetes despite metformin and glargine once daily titrated to 40 units. HbA1c is 8.5%, AM fasting blood glucose range 120-140 mg/dL, prandial blood glucose range 180-200 mg/dL. His BMI is 36.8 kg/m2. What is the next best step in diabetes management?
• ADA guidelines recommend to addition on non-insulin injectable before adding insulin in type 2 diabetes if no contraindications
• If patient is already on metformin and basal insulin, then addition of GLP-1 receptor agonist is associated with
• Similar HbA1c reduction• Less hypoglycemia• Weight loss v/s weight gain
1. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014
2. Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Grøn R, Halladin N, Jodar E. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care. 2018
10/12/2020
16
Case 6A 65-year-old-woman with type 2 diabetes for 15 years, CKD (eGFR 28), CAD injects 20 units glargine at bedtime and 7 units aspart with meals. Pre-meal blood glucose target is 100-140 mg/dL. Her BMI is 24 kg/m2, HbA1c is 8%. Her blood glucose log for last 7 days is as below. What is the best next adjustment to her insulin regimen?
Case 6A 65-year-old-woman with type 2 diabetes for 15 years, CKD (eGFR 28), CAD injects 20 units glargine at bedtime and 7 units aspart with meals. Pre-meal blood glucose target is 100-140 mg/dL. Her BMI is 24 kg/m2, HbA1c is 8%. Her blood glucose log for last 7 days is as below. What is the best next adjustment to her insulin regimen?
Principles of insulin dose adjustmentPrandial/meal-time insulin• BG should be in target
before the next meal
Long-acting/basal insulin• BG should stay level or
within 40 mg/dL overnight if not eating
Blood Glucose (BG) Before Breakfast:
Basal dose adjustment
40 mg/dL BELOW bedtime BG the night before
Decrease dose by 10%
Within 40 mg/dL of bedtime BG the night before
Continue current dose
ABOVE bedtime BG the night before (no snack)
Increase dose by 10%
Blood Glucose (BG) before NEXT meal
Prandial dose adjustment
Below goal range Decrease dose by 10%
Within goal range Continue current dose
Above goal range Increase dose by 10%
• “3-4 day pattern”• Seek the cause of hypoglycemia and adjust
insulin regimen accordingly
Take home pointsGLP-1 receptor agonists and SGLT-2 inhibitors with
beneficial effects on cardiovascular disease, heart failure and/or renal dysfunction should be preferred
Hypoglycemia risk and glycemic target should guide diabetes therapy
GLP-1 receptor agonist + basal insulin show similar HbA1c reduction with less hypoglycemia and more weight loss as compared to basal + prandial insulin
Insulin dose adjustment is based on recognizing a pattern of abnormal blood glucose